NCT07096193View on ClinicalTrials.gov

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Chronic Hepatitis Delta
Interventions
DRUG

GS-4321

Administered subcutaneous (SC) or intravenously IV

DRUG

GS-4321 Placebo

Administered SC

DRUG

GS-4321

Administered SC

Trial Locations (1)

92801

RECRUITING

Investigative Site, Anaheim

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY